Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159362 · ClinicalTrials.gov registry record · NA
Usability Testing for the Reward-based Technology to Improve OUD Treatment
A NA study, sponsored by Q2i.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT05159362 is a NA study that has completed, run by Q2i. The registered enrollment target is 26 participants.
The verdict
NCT05159362, a NA study, has completed, sponsored by Q2i.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common and associated with poor outcomes. This STTR Fast Track proposal is designed to increase rates of Suboxone (buprenorphine/naloxone) treatment initiation and adherence among OUD patients recruited from emergency and inpatient acute care. To accomplish these aims, the project will enhance the Opioid Addiction Recovery Support (OARS), an existing Q2i company technology, with a new evidence-based reward, contingency management (CM) function. CM interventions systematically reward (reinforce) specific behaviors like treatment initiation and adherence with therapy attendance and drug-free urine tests and are highly efficacious. An OARS solution enhanced with a CM component (OARSCM) that allows for the automatic calculation, delivery, and redemption of rewards contingent on objective evidence of treatment behaviors may be key to improving Suboxone initiation and adherence. In Phase 1 of this proposal, the existing OARS clinician portal and patient mobile application will be modified to accommodate entry into the software system from an acute care setting and to automatically manage and deliver rewards to create OARSCM using patient-centered design principles. Focus groups with OUD patients and other key stakeholders will inform design. Primary usability outcomes will be examined, and the program iteratively updated. After meeting milestones, there was a proof-of-concept pilot of usability, acceptability, and effects on initial behavior targets with approximately 20 patients and at least 4 providers.
Interventions
- OTHER Software Application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2021-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05159362
The ClinicalTrials.gov registry entry for NCT05159362 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Q2i, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Software Application is the first listed.
NCT05159362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05159362 about?
NCT05159362 is a clinical study titled "Usability Testing for the Reward-based Technology to Improve OUD Treatment". Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-ad...
What is the current status of trial NCT05159362?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2020-07-01. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT05159362?
The interventions under investigation include: Software Application (OTHER).
Who is sponsoring clinical trial NCT05159362?
This trial is sponsored by Q2i, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.